Logo image
Neoadjuvant Radiotherapy-Related Wound Morbidity in Soft Tissue Sarcoma: Perspectives for Radioprotective Agents
Journal article   Open access   Peer reviewed

Neoadjuvant Radiotherapy-Related Wound Morbidity in Soft Tissue Sarcoma: Perspectives for Radioprotective Agents

Cameron M Callaghan, M. M Hasibuzzaman, Samuel N Rodman, Jessica E Goetz, Kranti A Mapuskar, Michael S Petronek, Emily J Steinbach, Benjamin J Miller, Casey F Pulliam, Mitchell C Coleman, …
Cancers, Vol.12(8), pp.1-26
08/01/2020
DOI: 10.3390/cancers12082258
PMCID: PMC7465163
PMID: 32806601
url
https://doi.org/10.3390/cancers12082258View
Published (Version of record) Open Access

Abstract

Historically, patients with localized soft tissue sarcomas (STS) of the extremities would undergo limb amputation. It was subsequently determined that the addition of radiation therapy (RT) delivered prior to (neoadjuvant) or after (adjuvant) a limb-sparing surgical resection yielded equivalent survival outcomes to amputation in appropriate patients. Generally, neoadjuvant radiation offers decreased volume and dose of high-intensity radiation to normal tissue and increased chance of achieving negative surgical margins-but also increases wound healing complications when compared to adjuvant radiotherapy. This review elaborates on the current neoadjuvant/adjuvant RT approaches, wound healing complications in STS, and the potential application of novel radioprotective agents to minimize radiation-induced normal tissue toxicity.
Oncology Life Sciences & Biomedicine Science & Technology

Details

Metrics

Logo image